The utilization and safety of apixaban for therapeutic anticoagulation in heart transplant population requiring routine endomyocardial biopsies
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Transplantation"
DOI: 10.1111/ctr.14828
Abstract: Routine endomyocardial (EM) biopsies pose a challenge in the management of heart transplant recipients requiring anticoagulation. Apixaban is a direct‐acting oral anticoagulant (DOAC) with a short half‐life allowing for brief interruptions of anticoagulation for procedures.… read more here.
Keywords: routine endomyocardial; heart transplant; anticoagulation; endomyocardial biopsies ... See more keywords